The early history of the use of radioactive iodine (RAI) is complicated and interesting, and also difficult to discover, especially since several histories have presented inaccurate content. This ...article is a comprehensive review of the accomplishments of Saul Hertz. Extensive use of primary-source verification has clarified several issues, including the question of whether Hertz alone conceived and asked the pivotal question: "Could iodine be made radioactive artificially?"; on what date RAI was first used to treat hyperthyroidism; and why 2 articles on the first use of RAI for treatment of hyperthyroidism, from 2 different sets of authors from the same department of the same institution, appeared adjacent to each other in the same issue of the
in 1946. Our review also chronicles several major challenges that Hertz overcame to produce his pivotal work. Hertz was clearly the originator and a visionary of RAI therapy in benign and malignant thyroid disease. We believe he can be considered one of the fathers of nuclear medicine. Hertz's paradigm-changing work was a pivotal medical discovery of the 20th century. The legacy of Hertz continues while the application of RAI therapy continues to evolve. RAI therapy remains the preferred treatment in most situations for autonomous nodules and toxic multinodular goiter and remains a safe and effective treatment for Graves disease after more than 80 y of global clinical use. RAI treatment of differentiated thyroid cancer remains a first-line treatment for most patients after surgery, especially for those with intermediate- or high-risk disease.
SNMMI has convened a task group to examine the evidence of risk of carcinogenesis from low-dose radiation exposure. The task group is made up of individuals from various professional societies, ...including SNMMI, the Health Physics Society (HPS), the American Association of Physicists in Medicine (AAPM), and the American Society for Radiation Oncology (ASTRO). In their report, the members of the task group will express their personal views, without explicit endorsement or approval by any professional society. Such endorsement by HPS, AAPM, and ASTRO will be actively pursued.
Implementing the Value Initiative Greenspan, Bennett S
The Journal of nuclear medicine (1978),
06/2018, Letnik:
59, Številka:
6
Journal Article
Recenzirano
Greenspan highlights the progress made in the implementation of Society of Nuclear Medicine and Molecular Imaging's (SNMMI) Value Initiative and strategic plan. These include SNMMI's collaboration ...with experts representing multiple organizations to develop appropriate use criteria (AUC) for diagnostic and therapeutic procedures to ensure high-quality, value-driven, patient-centered care. For effective implementation of the AUC, the society has contracted with several clinical decision support platforms, including the National Decision Support Company's CareSelect system and Stanson Health.
This article discusses the role of PET/CT in contributing to precision medicine in lung cancer, and provides the perspective of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) on this ...process. The mission and vision of SNMMI are listed, along with the guidance provided by SNMMI to promote best practice in precision medicine. Basic principles of PET/CT are presented. An overview of the use of PET/CT imaging in lung cancer is discussed. In lung cancer patients, PET/CT is vitally important for optimal patient management. PET/CT is essential in determining staging and re-staging of disease, detecting recurrent or residual disease, evaluating response to therapy, and providing prognostic information. PET/CT is also critically important in radiation therapy planning by determining the extent of active disease, including an assessment of functional tumor volume. The current approach in tumor imaging is a significant advance over conventional imaging. However, recent advances suggest that therapeutic response criteria in the near future will be based on metabolic characteristics and will include the evaluation of biologic characteristics of tumors to further enhance the effectiveness of precision medicine in lung cancer, producing improved patient outcomes with less morbidity.
Advancing Research and Discovery Greenspan, Bennett S
The Journal of nuclear medicine (1978),
03/2018, Letnik:
59, Številka:
3
Journal Article
Recenzirano
Greenspan focuses on the growing the field of nuclear medicine and molecular imaging (NM/MI) by implementing the steps necessary to achieve the goals and objectives of our Value Initiative and new ...strategic plan. In the Research and Discovery Domain, chaired by Richard L. Wahl, MD, their goal is to advance the development and approval of NM/MI technologies. A key step in efforts to encourage and promote research in the field is to develop a broadbased vision document outlining the role of precision imaging and radiopharmaceutical therapy in cancer, neurodegeneration, and other medical conditions that can be used in funding requests. An ad hoc research committee (made up of experts from the SNMMI Clinical Trials Network, Centers of Excellence, Programming Committee, Council chairs, etc.) is taking the lead on this and will oversee creation of an overarching paper, as well as brochures for specific areas of interest.
PDF
